The Peony trial: adding evidence to pertuzumab use in non-metastatic breast cancer

摘要

In the past 10 years, neoadjuvant chemotherapy (NAC) has become a common tool in our hospitals, in order to convert the unresecables tumors into resecable and to increase the rate of conservative surgeries. Having a pathological response to NAC is an independent prognostic factor o and we cannot forget that NAC allows us to carry out clinical trials with new molecules. For those reasons, nowadays a few T2 tumors receive NAC regularly, especially HER2 molecular subtypes, which globally represent 20% of the tumors that we see in our offices. HER2-positive tumors are the ones that will undergo NAC and immunotherapy because they are very sensitive to these treatments, and surgeons are doing lumpectomys with very low load of tumor at the surgical specimen.